---
schema_version: "secwatch.filing_event.v1"
accession: "0001645666-25-000036"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T13:56:58.410499+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences Q2 net loss $13.7M; FDA lifts partial hold on AIH trial

## Summary
- Net loss $13.7M ($1.87/share) vs $21.5M loss in Q2 2024; R&D expenses down 41% to $9.6M.
- Cash, equivalents & marketable securities $100.8M as of June 30, 2025 ($132.2M at Dec 31, 2024).
- FDA removed partial clinical hold on PORTOLA Phase 2a trial for zetomipzomib in autoimmune hepatitis.
- Submitted Type C meeting request to FDA for Q4 2025 to discuss registration-enabling AIH study design.
- PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting 2025 (Nov 7-11).

## SEC filing metadata
- accession: 0001645666-25-000036
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/0001645666-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000036/kzr-20250813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645666-25-000036
- JSON: https://secwatch.observer/filing/0001645666-25-000036.json
- Plain text: https://secwatch.observer/filing/0001645666-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.